Literature DB >> 27859864

l-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role?

Anna R Carta1, Giovanna Mulas1, Mariza Bortolanza2,3, Terence Duarte2,3, Elisabetta Pillai1, Gilberto Fisone4, Rita Raisman Vozari5, Elaine Del-Bel2.   

Abstract

In Parkinson's disease (PD), l-DOPA therapy leads to the emergence of motor complications including l-DOPA-induced dyskinesia (LID). LID relies on a sequence of pre- and postsynaptic neuronal events, leading to abnormal corticostriatal neurotransmission and maladaptive changes in striatal projection neurons. In recent years, additional non-neuronal mechanisms have been proposed to contribute to LID. Among these mechanisms, considerable attention has been focused on l-DOPA-induced inflammatory responses. Microglia and astrocytes are the main actors in neuroinflammatory responses, and their double role at the interface between immune and neurophysiological responses is starting to be elucidated. Both microglia and astrocytes express a multitude of neurotransmitter receptors and via the release of several soluble molecules modulate synaptic function in neuronal networks. Here we review preclinical and clinical evidence of glial overactivation by l-DOPA, supporting a role of microglia and astrocytes in the development of LID. We propose that in PD, chronically and abnormally activated microglia and astrocytes lead to an aberrant neuron-glia communication, which affect synaptic activity and neuroplasticity contributing to the development of LID.
© 2016 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  Parkinson's disease; cytokine; inducible nitric oxide synthase; nitric oxide; tumor necrosis factor-α

Mesh:

Substances:

Year:  2016        PMID: 27859864     DOI: 10.1111/ejn.13482

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  23 in total

1.  Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  D P Ferrari; M Bortolanza; E A Del Bel
Journal:  Neurotox Res       Date:  2021-03-09       Impact factor: 3.911

2.  Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.

Authors:  Erinaldo Ubirajara Damasceno Dos Santos; Elaine Bandeira Cavalcanti Duarte; Laura Maria Ramos Miranda; Andore Guescel C Asano; Nadja Maria Jorge Asano; Maria de Mascena Diniz Maia; Paulo Roberto Eleutério de Souza
Journal:  Neuromolecular Med       Date:  2019-05-22       Impact factor: 3.843

Review 3.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

4.  Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.

Authors:  Kathryn Lanza; Amy E Perkins; Terrence Deak; Christopher Bishop
Journal:  Neurobiol Aging       Date:  2019-05-31       Impact factor: 4.673

5.  Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.

Authors:  Qiu-Shuang Zhang; Yang Heng; Zheng Mou; Ju-Yang Huang; Yu-He Yuan; Nai-Hong Chen
Journal:  Acta Pharmacol Sin       Date:  2017-06-26       Impact factor: 6.150

Review 6.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

7.  Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in L-Dopa-induced dyskinesia in parkinsonian rats.

Authors:  Shetty Ravi Dyavar; Lisa F Potts; Goichi Beck; Bhagya Laxmi Dyavar Shetty; Benton Lawson; Anthony T Podany; Courtney V Fletcher; Rama Rao Amara; Stella M Papa
Journal:  Genes Brain Behav       Date:  2020-09-11       Impact factor: 3.449

8.  Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease.

Authors:  Seyma Bahdoudi; Ikram Ghouili; Mansour Hmiden; Jean-Luc do Rego; Benjamin Lefranc; Jérôme Leprince; Julien Chuquet; Jean-Claude do Rego; Ann-Britt Marcher; Susanne Mandrup; Hubert Vaudry; Marie-Christine Tonon; Mohamed Amri; Olfa Masmoudi-Kouki; David Vaudry
Journal:  Cell Mol Life Sci       Date:  2017-12-20       Impact factor: 9.261

9.  Testing alternatives: the use of adipose-derived mesenchymal stem cells to slow neurodegeneration in a rat model of Parkinson's disease.

Authors:  Fatma Y Meligy; Dalia A Elgamal; Eman S H Abd Allah; Naglaa K Idriss; Nagwa M Ghandour; Ehab M R Bayoumy; Azza Sayed Abdelrehim Khalil; Mohamed M El Fiky; Mostafa Elkhashab
Journal:  Mol Biol Rep       Date:  2019-08-08       Impact factor: 2.316

10.  Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson's Disease.

Authors:  Elena Contaldi; Luca Magistrelli; Anna Vera Milner; Marco Cosentino; Franca Marino; Cristoforo Comi
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.